Skip to main content
TipRanks
Go Ultimate75% OFF

Aethlon Medical (AEMD) Q1 2027 Earnings Report

601 Followers

AEMD Q1 2027 EPS Results

Actual EPS
-$4.02
Consensus EPS
-$3.93
Beat/Miss
Missed by -$0.09
One Year Ago EPS
-$42.50

AEMD Q1 2027 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q1 2027
Date
08/13/2026
Time
After Close
Conference Call
Thursday, August 13, 2026
AEMD Upcoming Earnings

Aethlon Medical's next earnings date is estimated for February 15, 2027, based on past reporting schedules.

Q1 2027 Earnings Call Audio

AEMD Q1 2027 Earnings Call
0:00 / 0:00

Q1 2027 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2027 Earnings Call Summary

Q1 2027
Earnings Call Date:Aug 13, 2026|% Change Since:65.19%|
Earnings Call Sentiment|Neutral

The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.

Company Guidance

The company provided specific operational and clinical guidance: for the fiscal Q1 ended June 30, 2026 it reported approximately $4.9M in cash (and subsequently raised ~ $4M in gross proceeds), believes cash is sufficient to fund operations for at least the next 12 months, and cut consolidated operating expenses 11.9% to about $1.6M (from $1.8M a year earlier); clinically, Aethlon is in the final (third) cohort of its Australian oncology trial (needs 2 more participants to complete treatment if no device-related SAEs or dose‑limiting toxicities occur), Cohort 3’s first patient received three 4‑hour Hemopurifier treatments over one week and is 8 weeks into follow‑up with no device‑related SAEs/DTLs, Cohort 2 (three participants) received two 4‑hour treatments and Cohort 1 received one 4‑hour treatment, central lab measurements of EVs, microRNAs and lymphocyte subsets for Cohort 2 are complete and showed decreases in total and tumor‑derived EVs, reductions in microRNAs linked to cancer progression, and increases in lymphocyte subsets with directional biomarker changes that persisted to 8 weeks (vs ~2–3 weeks in Cohort 1); next steps are data analysis, a clinical study report, preregistration discussions with regulators, and a goal to complete all Hemopurifier treatments and the 8‑week follow‑up period by end of calendar 2026 (or early 2027).

  • Advancement to Final Cohort of Australian Oncology TrialCompany is in the third and final cohort of the Australian oncology trial; first participant in Cohort 3 treated and completed 8-week follow-up without device-related serious adverse events or dose-limiting toxicity. Only two additional participants are required to complete the trial (subject to no future safety events). Goal to complete all Hemopurifier (HP) treatments and 8-week follow-up central lab measurements by end of calendar 2026 (or early 2027).
  • Encouraging Cohort 2 Biomarker ObservationsCentral lab measurements on Cohort 2 (participants received two 4-hour HP treatments in one week) showed decreases in total extracellular vesicle (EV) counts including tumor-derived EVs and microRNAs linked to cancer progression, increases in lymphocyte subsets, and positive directional changes in lab parameter ratios associated with immunotherapy response. Changes in Cohort 2 were more consistent across participants and appeared to persist longer (up to 8 weeks) versus Cohort 1.
  • Peer-Reviewed Long COVID Preclinical Data PublishedJune 25, 2026 publication in International Journal of Molecular Sciences demonstrating that small and large extracellular vesicles in Long COVID patient plasma bind to the proprietary GNA affinity resin used by the Hemopurifier, with subsequent decreases in microRNAs associated with immune dysregulation and inflammation — supporting potential new application areas and prompting plans for academic and regulatory discussions.
  • Platform Expansion and R&D ProgressActive preclinical research expanding Hemopurifier evaluation into additional disease areas (Long COVID, lupus, heart disease in chronic kidney disease), ongoing experiments showing ability to bind/remove disease-implicated EVs, and continued generation of intellectual property and clinical development progress.
  • Strengthened Balance Sheet and Cash RunwayCash and cash equivalents of approximately $4.9 million at June 30, 2026, and subsequent gross proceeds of approximately $4.0 million raised in a public offering after quarter end. Company believes cash resources are sufficient to fund operations for at least the next 12 months (implying a post-offering cash position of roughly $8.9 million, subject to closing adjustments and use of proceeds).
  • Disciplined Cost Control and Lower Operating ExpensesConsolidated operating expenses decreased 11.9% year-over-year to approximately $1.6 million for the quarter (down from $1.8 million in the prior-year quarter), driven by lower professional fees, reduced general and administrative costs and lower preclinical research spending; operating loss declined accordingly.

AEMD Earnings History

AEMD earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 15, 20272027 (Q3)-1.71--12.25――
Nov 12, 20262027 (Q2)-2.70-2.60-18.786.10% (+16.10)
Aug 13, 20262027 (Q1)-3.92-4.02-42.590.54% (+38.48)
Jun 10, 20262026 (Q4)-10.8320.40-161112.67% (+181.40)
Feb 12, 20262026 (Q3)-13.75-12.25-5276.44% (+39.75)
Nov 12, 20252026 (Q2)-18.32-18.70-8076.63% (+61.30)
Aug 13, 20252026 (Q1)-43.05-42.50-13668.75% (+93.50)
Jun 26, 20252025 (Q4)-53.67-161.00-34853.74% (+187.00)
Feb 12, 20252025 (Q3)-81.33-52.00-54890.51% (+496.00)
Nov 13, 20242025 (Q2)-78.00-80.00-48883.61% (+408.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed